International Clinical Trial: Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463677) titled 'Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on March 1.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Sun Yat-sen University

Condition: Lung Cancer (NSCLC)

Intervention: Drug: Tunlametinib + Cetuximab ß

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 15, 2026

Target Sample Size: 55

To know more, visit https://clinicaltrials.gov/study/NCT0746367...